# Rocket Pharmaceuticals

Type: Company (RCKT)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/rocket-pharmaceuticals
Canonical HTML page: https://getbiobrief.com/entity/rocket-pharmaceuticals

## Timeline

- **2026-03-19**: Stock Volatility — RCKT shares decline 4.4% amid sector-wide growth stock pressure and regulatory uncertainty.
- **2026-03-10**: SEC Filing 8-K — Company enters into a new material definitive agreement and terminates a previous facility.
- **2026-02-26**: FY 2025 Earnings — Rocket Pharmaceuticals reports full-year 2025 results and provides pipeline updates.

## Recent coverage (1 stories)

### Rocket Pharmaceuticals Shares Slide 4.4% Amid Regulatory and Financing Shifts
2026-03-19 21:01:26 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Rocket Pharmaceuticals (RCKT) shares declined 4.4% on March 19, 2026, as investors weighed a recent shift in the company's financial agreements against ongoing regulatory timelines for its lead gene therapy programs. The drop outpaced broader market movements, reflecting specific volatility in the rare disease gene therapy sector.
Full story: https://getbiobrief.com/story/rocket-pharmaceuticals-rckt-stock-drop-analysis-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.